Project Details
| Status | Active |
|---|---|
| Effective start/end date | 18/01/24 → 17/01/29 |
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
- Shortt, Jake (Primary Chief Investigator (PCI))
- Gregory, Gareth (Chief Investigator (CI))
Project: Research